Compare CMTL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | IFRX |
|---|---|---|
| Founded | 1967 | 2007 |
| Country | United States | Germany |
| Employees | 1385 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.1M | 60.6M |
| IPO Year | 2024 | 2017 |
| Metric | CMTL | IFRX |
|---|---|---|
| Price | $4.67 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 221.6K | 171.7K |
| Earning Date | 03-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,528,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.97 | $1,054.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.19 | $0.71 |
| 52 Week High | $6.21 | $1.94 |
| Indicator | CMTL | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 52.69 |
| Support Level | $2.74 | $0.75 |
| Resistance Level | $6.15 | $1.16 |
| Average True Range (ATR) | 0.37 | 0.07 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 3.57 | 50.85 |
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.